同和药业(300636) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥206,454,983.02, a decrease of 6.47% compared to ¥220,746,478.69 in the same period last year[5] - Net profit attributable to shareholders increased by 31.62% to ¥43,562,751.14 from ¥33,096,474.74 year-on-year[5] - Basic earnings per share rose by 9.74% to ¥0.1037, compared to ¥0.0945 in the same period last year[5] - The operating profit for the first quarter was CNY 49,031,953.90, up from CNY 35,018,129.78, indicating a growth of 40.0% year-over-year[24] - The total revenue from operating activities was CNY 156,938,328.08, a decrease of 18.6% from CNY 192,740,643.47 in the previous year[25] Cash Flow - The net cash flow from operating activities decreased significantly by 65.12% to ¥29,743,589.13, down from ¥85,264,632.48 in the previous year[11] - The cash flow from operating activities showed a net inflow of CNY 29,743,589.13, down 65.1% from CNY 85,264,632.48 in the same quarter last year[27] - The net cash flow from financing activities increased by 89.75% to ¥150,196,833.20, driven by increased borrowings[11] - The total cash inflow from financing activities was CNY 304,950,000.00, up from CNY 180,279,576.00, showing a strong increase in financing efforts[27] Assets and Liabilities - Total assets increased by 5.26% to ¥3,390,868,839.82 from ¥3,221,439,738.99 at the end of the previous year[5] - The company's total liabilities increased to ¥1,119,421,778.18 from ¥994,990,614.72, reflecting a rise of about 12.5%[22] - Non-current assets totaled ¥2,106,094,358.02, up from ¥2,024,456,028.48, marking an increase of approximately 4.0%[21] - The company's equity attributable to shareholders rose to ¥2,271,447,061.64 from ¥2,226,449,124.27, an increase of approximately 2.0%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 14,649[12] - The largest shareholder, Mr. Pang Zhengwei, holds 15.60% of the shares, amounting to 66,009,954 shares, with 13,860,000 shares pledged[12] - The second-largest shareholder, Fenglong Industrial Co., Ltd., holds 13.12% of the shares, totaling 55,511,352 shares[12] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for 30.42% of the total shares[12] Research and Development - Research and development expenses decreased by 46.42% to ¥10,292,403.05 from ¥19,210,151.13 year-on-year[10] - Research and development expenses amounted to CNY 10,292,403.05, a decrease of 46.5% compared to CNY 19,210,151.13 in the previous year[24] Operational Developments - The company completed the construction of the main structure for the new plant project, with some buildings undergoing external decoration as of 2022[18] - The company has completed the expansion and renovation of certain workshops and facilities in the new plant area, enhancing production capacity[18] Other Income and Expenses - Other income surged by 904.91% to ¥3,685,602.25, primarily due to increased government subsidies[10] - The company experienced a 190.08% increase in income tax expenses, amounting to ¥5,402,452.76, due to higher taxable income[10] - The company incurred financial expenses of CNY -5,567,941.04, contrasting with CNY 3,000,752.72 in the previous year, indicating a shift in financial management[24] Future Outlook - The report does not provide specific future performance guidance or outlook for the upcoming quarters[12] - The company has not disclosed any new strategies related to market expansion or mergers and acquisitions in this report[12] - There are no new product launches or technological developments mentioned in the current quarter's report[12] - The report indicates that there are no changes in the number of restricted shares for major shareholders during the reporting period[15] - The company has not reported any changes in the participation of major shareholders in margin financing or securities lending activities[13]